亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

B32-15 Depemokimab Demonstrates Sustained Long-term Efficacy and Consistent Patient-reported Outcomes Over 2 Years in Patients With Type 2 Asthma: An Integrated Analysis of the SWIFT-1/-2 and AGILE Studies

作者
I D Pavord,Pascal Chanez,C-Q Zhu,Diana Jarreta,C Tacon,Anna Vichiendilokkul,Michael E. Wechsler
出处
期刊:American Journal of Respiratory and Critical Care Medicine [American Thoracic Society]
卷期号:212 (Supplement_1) 被引量:1
标识
DOI:10.1093/ajrccm/aamag162.455
摘要

Abstract Rationale Depemokimab is the first ultra-long-acting biologic, with enhanced interleukin-5 binding affinity, high potency, and extended half-life, enabling twice-yearly dosing in asthma. Depemokimab efficacy has been demonstrated in Phase III SWIFT-1/-2 studies in patients with type 2 (T2) asthma. Here we assess depemokimab long-term efficacy in an integrated post hoc analysis of the SWIFT-1/-2 and AGILE open-label extension (OLE) studies. Methods Eligible adults with T2 asthma characterized by blood eosinophil counts (BEC) were randomized 2:1 to receive subcutaneous depemokimab 100 mg or placebo every 26 weeks for 52 weeks in SWIFT-1/-2. Patients who completed SWIFT-1/-2 were invited to join the single-arm AGILE OLE study, continuing with depemokimab (depemokimab/depemokimab group) or switching from placebo to depemokimab (placebo/depemokimab group) with follow-up for a total period of 104 weeks. Efficacy endpoints included annualized exacerbation rate (AER), least squares mean (SE) change from baseline (CFB) at the start of SWIFT-1/-2 in St George’s Respiratory Questionnaire (SGRQ) total score, Asthma Control Questionnaire (ACQ)-5 score over 104 weeks, and BEC over time. Results In SWIFT-1/-2 (N = 762), AER (95% CI) over 52 weeks was 0.51 (0.43, 0.60) in the depemokimab group (n = 502), representing a 54% reduction versus placebo (AER [95% CI]: 1.11 [0.92, 1.33]; n = 260). Overall, 641 (84%) patients entered AGILE; 629 received ≥1 depemokimab dose and were included in the integrated analysis (n = 419, depemokimab/depemokimab; n = 210, placebo/depemokimab). AER reduction was maintained over the full 2-year SWIFT/AGILE period in the depemokimab/depemokimab group (0.52 [0.45, 0.60]). CFB in SGRQ total score with depemokimab at Week 52 of SWIFT-1/-2 was −13.92 (0.76), with maintenance of the response in the depemokimab/depemokimab group over the 2-year SWIFT/AGILE period (CFB at Week 104: −16.29 [0.85]). Similarly, CFB in ACQ-5 score with depemokimab at Week 52 in SWIFT-1/-2 was −0.81 (0.05); this reduction was sustained across the 2-year period (CFB at Week 104: −0.89 [0.05]). Suppression of T2 inflammation, assessed by BEC, was consistent throughout the 2-year period in the depemokimab/depemokimab group (ratio to baseline [SE logs] at Week 104: 0.174 [0.04]). Rapid and clinically relevant improvements in clinical outcomes were also observed during Year 2 in patients who switched from placebo to depemokimab at Week 52. These improvements were sustained through to end of treatment. Conclusions Depemokimab showed sustained suppression of inflammation and clinically meaningful efficacy which was maintained over a 2-year period in patients with T2 asthma. These results support the long-term efficacy of depemokimab in asthma. This abstract is funded by: GSK (SWIFT-1/-2: 206713/213744, NCT04719832/NCT04718103; AGILE: 212895/NCT05243680).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
aa完成签到,获得积分10
1秒前
LSQ完成签到,获得积分10
8秒前
14秒前
foden完成签到,获得积分10
15秒前
xinran完成签到,获得积分10
20秒前
温暖的帆布鞋完成签到,获得积分10
23秒前
yli130完成签到,获得积分10
24秒前
24秒前
30秒前
Sarahminn发布了新的文献求助10
31秒前
33秒前
俏皮的灵发布了新的文献求助10
34秒前
机灵的沂完成签到,获得积分10
46秒前
奔跑的应助被虚心的灵寒采纳,获得10
47秒前
奔跑的应助被虚心的灵寒采纳,获得10
47秒前
欢呼的兰完成签到,获得积分10
50秒前
华仔的应助被lmn采纳,获得10
54秒前
酒酿是也完成签到 ,获得积分10
54秒前
满意的楷瑞完成签到,获得积分10
56秒前
顺利的水瑶完成签到 ,获得积分10
58秒前
1分钟前
我是老大的应助被科研通管家采纳,获得10
1分钟前
彭于晏的应助被科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
慕青的应助被肖可声采纳,获得10
1分钟前
田様的应助被重要白亦采纳,获得10
1分钟前
科研通AI6.2的应助被Jeff采纳,获得20
1分钟前
科研通AI6.3的应助被Jeff采纳,获得50
1分钟前
烟花的应助被俏皮的灵采纳,获得10
1分钟前
lmn发布了新的文献求助10
1分钟前
1分钟前
Maestro_S的应助被Kaikai采纳,获得10
1分钟前
1分钟前
肖可声完成签到,获得积分10
1分钟前
mino完成签到 ,获得积分10
1分钟前
1分钟前
肖可声发布了新的文献求助10
1分钟前
铃木完成签到,获得积分10
1分钟前
重要白亦发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172954
求助须知:如何正确求助?哪些是违规求助? 9565447
关于积分的说明 21780029
捐赠科研通 7764817
什么是DOI,文献DOI怎么找? 3431496
关于科研通互助平台的介绍 2555519
邀请新用户注册赠送积分活动 2476571